{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:14Z","timestamp":1791348734338,"version":"4.3.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81070171"],"award-info":[{"award-number":["81070171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81241121"],"award-info":[{"award-number":["81241121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013286","name":"Specialized Research Fund for the Doctoral Program of Higher Education of China","doi-asserted-by":"crossref","award":["20111106110013"],"award-info":[{"award-number":["20111106110013"]}],"id":[{"id":"10.13039\/501100013286","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Capital Special Foundation of Clinical Application Research","award":["Z121107001012015"],"award-info":[{"award-number":["Z121107001012015"]}]},{"name":"Capital Health Development Fund","award":["2011400302"],"award-info":[{"award-number":["2011400302"]}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7131014"],"award-info":[{"award-number":["7131014"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.cca.2016.06.016","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T21:33:03Z","timestamp":1466631183000},"page":"50-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Apoprotein C-III: A review of its clinical implications"],"prefix":"10.1016","volume":"460","author":[{"given":"Jing-Lu","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1251-6074","authenticated-orcid":false,"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2016.06.016_bb0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2016.06.016_bb0010","first-page":"1383","article-title":"Randomized trial of cholesterollowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2016.06.016_bb0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/CIRCULATIONAHA.106.667428","article-title":"Lipid management to reduce cardiovascular risk: a new strategy is required","volume":"117","author":"Superko","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2016.06.016_bb0020","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and TGs in statin-treated patients: a clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.cca.2016.06.016_bb0025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2016.06.016_bb0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2016.06.016_bb0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2796.2010.02333.x","article-title":"Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31years of follow-up","volume":"270","author":"Langsted","year":"2011","journal-title":"J. Intern. Med."},{"issue":"7","key":"10.1016\/j.cca.2016.06.016_bb0040","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22Trial","volume":"51","author":"Miller","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2016.06.016_bb0045","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2016.06.016_bb0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2016.06.016_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2016.06.016_bb0060","doi-asserted-by":"crossref","first-page":"13268","DOI":"10.1016\/S0021-9258(18)69300-7","article-title":"Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III, and A-IV genes","volume":"261","author":"Haddad","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.cca.2016.06.016_bb0065","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1016\/S0021-9258(18)63614-2","article-title":"Studies of the proteins in human plasma very low density lipoproteins","volume":"244","author":"Brown","year":"1969","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cca.2016.06.016_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0079-6107(03)00028-2","article-title":"On the structure and function of apolipoproteins: more than a family of lipid-binding proteins","volume":"83","author":"Bolanos-Garcia","year":"2003","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.cca.2016.06.016_bb0075","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0022-2275(20)34443-6","article-title":"Plasma lipoproteins: apolipoprotein structure and function","volume":"25","author":"Mahley","year":"1984","journal-title":"J. Lipid Res."},{"issue":"10","key":"10.1016\/j.cca.2016.06.016_bb0080","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI200419992","article-title":"Foxo1 mediates insulin action on apoC-III and triglyceride metabolism","volume":"114","author":"Altomonte","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.cca.2016.06.016_bb0085","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/S0022-2275(20)39938-7","article-title":"Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels","volume":"35","author":"Chen","year":"1994","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.06.016_bb0090","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/ATVBAHA.110.220723","article-title":"Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia","volume":"31","author":"Caron","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"30","key":"10.1016\/j.cca.2016.06.016_bb0095","doi-asserted-by":"crossref","first-page":"27120","DOI":"10.1074\/jbc.M203421200","article-title":"Orphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter","volume":"277","author":"Coste","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cca.2016.06.016_bb0100","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0016-5085(03)00896-5","article-title":"Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression","volume":"125","author":"Claudel","year":"2003","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.cca.2016.06.016_bb0105","doi-asserted-by":"crossref","first-page":"13470","DOI":"10.1074\/jbc.270.22.13470","article-title":"Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III","volume":"270","author":"Hertz","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cca.2016.06.016_bb0110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cmet.2010.09.001","article-title":"Regulation of hepatic ApoC3 expression by PGC-1\u03b2 mediates hypolipidemic effect of nicotinic acid","volume":"12","author":"Hernandez","year":"2010","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.cca.2016.06.016_bb0115","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/hep.24072","article-title":"Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance","volume":"53","author":"Kozlitina","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cca.2016.06.016_bb0120","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00041433-199706000-00005","article-title":"Apolipoprotein C-III gene variation and dyslipidaemia","volume":"8","author":"Talmud","year":"1997","journal-title":"Curr. Opin. Lipidol."},{"issue":"2\u20133","key":"10.1016\/j.cca.2016.06.016_bb0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0021-9150(91)90026-Y","article-title":"Variation at the apoAI\/CIII\/AIV gene complex is associated with elevated plasma levels of apoCIII","volume":"87","author":"Shoulders","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2016.06.016_bb0130","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1371\/journal.pbio.0040113","article-title":"Lipoprotein genotype and conserved pathway for exceptional longevity in humans","volume":"4","author":"Atzmon","year":"2006","journal-title":"PLoS Biol."},{"key":"10.1016\/j.cca.2016.06.016_bb0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0006-291X(72)80149-9","article-title":"Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein","volume":"46","author":"Brown","year":"1972","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2016.06.016_bb0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/01.RES.33.4.403","article-title":"Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins","volume":"33","author":"Krauss","year":"1973","journal-title":"Circ. Res."},{"key":"10.1016\/j.cca.2016.06.016_bb0145","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI111711","article-title":"Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein CIII","volume":"75","author":"Wang","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2016.06.016_bb0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0005-2760(86)90170-0","article-title":"Comparison of apolipoprotein C-II-deficient triacylglycerol-rich lipoproteins and trioleoylglycerol\/phosphatidylcholine-stabilized particles as substrates for lipoprotein lipase","volume":"875","author":"Jackson","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cca.2016.06.016_bb0155","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoproteinlipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.06.016_bb0160","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.109.875807","article-title":"Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype","volume":"121","author":"Zheng","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2016.06.016_bb0165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1194\/M900346-JLR200","article-title":"Expression of apolipoprotein C-III inMcA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions","volume":"51","author":"Sundaram","year":"2010","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.cca.2016.06.016_bb0170","doi-asserted-by":"crossref","first-page":"e00247","DOI":"10.1002\/phy2.247","article-title":"Overexpression ofapolipoprotein C-III of dietary triglyceride into lymph","volume":"2","author":"Wang","year":"2014","journal-title":"Phys. Rep."},{"issue":"7897","key":"10.1016\/j.cca.2016.06.016_bb0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0140-6736(75)92376-4","article-title":"Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease","volume":"1","author":"Miller","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2016.06.016_bb0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cca.2016.06.016_bb0185","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.111.000232","article-title":"Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease","volume":"1","author":"Jensen","year":"2012","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.cca.2016.06.016_bb0190","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.112.108753","article-title":"Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling","volume":"127","author":"Riwanto","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2016.06.016_bb0200","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1194\/jlr.P600011-JLR200","article-title":"Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions","volume":"48","author":"Zheng","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2016.06.016_bb0205","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/ATVBAHA.109.197830","article-title":"Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins","volume":"30","author":"Mendivil","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5298","key":"10.1016\/j.cca.2016.06.016_bb0210","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1126\/science.275.5298.391","article-title":"A mouse model with features of familial combined hyperlipidemia","volume":"275","author":"Masucci-Magoulas","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cca.2016.06.016_bb0215","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.ATV.0000249620.68705.0d","article-title":"Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation","volume":"27","author":"Kawakami","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2016.06.016_bb0220","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIRCULATIONAHA.105.591743","article-title":"Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells","volume":"113","author":"Kawakami","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2016.06.016_bb0225","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.622514","article-title":"Apolipoprotein C III induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells","volume":"114","author":"Kawakami","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2016.06.016_bb0230","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.RES.84.9.1085","article-title":"Very low-density lipoprotein activates nuclear factor-\u03baB in endothelial cells","volume":"84","author":"Dichtl","year":"1999","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.cca.2016.06.016_bb0235","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1161\/01.RES.84.11.1237","article-title":"Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice","volume":"84","author":"Ramos","year":"1999","journal-title":"Circ. Res."},{"issue":"27","key":"10.1016\/j.cca.2016.06.016_bb0240","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1073\/pnas.0403551101","article-title":"Apolipoprotein CIII promotes Ca2+-dependent beta cell deathin type 1 diabetes","volume":"101","author":"Juntti-Berggren","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"26","key":"10.1016\/j.cca.2016.06.016_bb0245","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1073\/pnas.1019553108","article-title":"Lowering apolipoprotein CIII delays onset of type 1 diabetes","volume":"108","author":"Holmberg","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.cca.2016.06.016_bb0250","doi-asserted-by":"crossref","first-page":"E2611","DOI":"10.1073\/pnas.1423849112","article-title":"Apolipoprotein CIII links islet insulin resistance to beta-cell failure in diabetes","volume":"112","author":"\u00c5vall","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.cca.2016.06.016_bb0255","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1161\/ATVBAHA.115.305415","article-title":"Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics","volume":"35","author":"Qamar","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.cca.2016.06.016_bb0260","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1056\/NEJMoa0907295","article-title":"Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease","volume":"362","author":"Petersen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"38","key":"10.1016\/j.cca.2016.06.016_bb0265","doi-asserted-by":"crossref","first-page":"14010","DOI":"10.3748\/wjg.v20.i38.14010","article-title":"Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population","volume":"20","author":"Li","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2016.06.016_bb0275","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1476-511X-10-93","article-title":"Lack of effect of apolipoprotein C3 polymorphisms on indices of liversteatosis, lipid profile and insulin resistance in obese Southern Europeans","volume":"10","author":"Sentinelli","year":"2011","journal-title":"Lipids Health Dis."},{"issue":"10","key":"10.1016\/j.cca.2016.06.016_bb0280","doi-asserted-by":"crossref","first-page":"e23100","DOI":"10.5812\/hepatmon.23100","article-title":"ApolipoproteinC3 gene polymorphisms are not a risk factor for developing non-alcoholic fatty liver disease: a meta-analysis","volume":"14","author":"Zhang","year":"2014","journal-title":"Hepat. Mon."},{"issue":"4","key":"10.1016\/j.cca.2016.06.016_bb0285","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.arcmed.2006.10.013","article-title":"APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome","volume":"38","author":"Miller","year":"2007","journal-title":"Arch. Med. Res."},{"issue":"5","key":"10.1016\/j.cca.2016.06.016_bb0290","doi-asserted-by":"crossref","first-page":"e5465","DOI":"10.1371\/journal.pone.0005465","article-title":"Apolipoprotein C3 polymorphisms, cognitive function and diabetes in Caribbean origin Hispanics","volume":"4","author":"Smith","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2016.06.016_bb0295","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12944-015-0047-9","article-title":"Effect of apolipoprotein C3 genetic polymorphisms on serum lipid levels and the risk of intracerebral hemorrhage","volume":"14","author":"Jiang","year":"2015","journal-title":"Lipids Health Dis."},{"issue":"12","key":"10.1016\/j.cca.2016.06.016_bb0300","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jnutbio.2004.07.001","article-title":"Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women","volume":"15","author":"Fernandez","year":"2004","journal-title":"J. Nutr. Biochem."},{"issue":"10","key":"10.1016\/j.cca.2016.06.016_bb0305","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin. Sci."},{"issue":"1","key":"10.1016\/j.cca.2016.06.016_bb0310","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.ejcn.1602673","article-title":"Kinetics of plasma apolipoprotein C-III as a determinant of diet-induced changes in plasma triglyceride levels","volume":"62","author":"Desroches","year":"2008","journal-title":"Eur. J. Clin. Nutr."},{"issue":"6","key":"10.1016\/j.cca.2016.06.016_bb0315","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/ajcn\/85.6.1527","article-title":"Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-III bound to apolipoprotein B-containing lipoproteins","volume":"85","author":"Shin","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"issue":"16","key":"10.1016\/j.cca.2016.06.016_bb0330","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1161\/01.CIR.102.16.1886","article-title":"VLDL, apolipoproteins B, CIII and E and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2016.06.016_bb0335","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/eurheartj\/ehs271","article-title":"Statins suppress apolipoprotein CIII induced vascular endothelial cell activation and monocyte adhesion","volume":"34","author":"Zheng","year":"2013","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.cca.2016.06.016_bb0340","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/bbrc.2000.3868","article-title":"Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone","volume":"278","author":"Sakamoto","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.cca.2016.06.016_bb0345","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1185\/030079903125004277","article-title":"Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe","volume":"20","author":"Kosoglou","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.cca.2016.06.016_bb0350","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.cca.2016.06.016_bb0355","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.cca.2016.06.016_bb0360","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N. Engl. J. Med."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898116302613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898116302613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T01:48:23Z","timestamp":1656726503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898116302613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":68,"alternative-id":["S0009898116302613"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2016.06.016","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apoprotein C-III: A review of its clinical implications","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2016.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}